0001193125-17-203322.txt : 20170614 0001193125-17-203322.hdr.sgml : 20170614 20170614135733 ACCESSION NUMBER: 0001193125-17-203322 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20170614 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170614 DATE AS OF CHANGE: 20170614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PERRIGO Co plc CENTRAL INDEX KEY: 0001585364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0627 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36353 FILM NUMBER: 17910862 BUSINESS ADDRESS: STREET 1: TREASURY BUILDING STREET 2: LOWER GRAND CANAL STREET CITY: DUBLIN STATE: L2 ZIP: L2 2 BUSINESS PHONE: 269-673-8451 MAIL ADDRESS: STREET 1: 515 EASTERN AVENUE CITY: ALLEGAN STATE: MI ZIP: 49010 FORMER COMPANY: FORMER CONFORMED NAME: PERRIGO Co Ltd DATE OF NAME CHANGE: 20130828 8-K 1 d413961d8k.htm FORM 8-K FORM 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 14, 2017

 

 

Perrigo Company plc

(Exact name of registrant as specified in its charter)

 

 

Commission file number 001-36353

 

Ireland   Not Applicable

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland   —
(Address of principal executive offices)   (Zip Code)

+353 1 7094000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01. Other Events

On June 14, 2017, Perrigo Company plc (“Perrigo”) issued a press release announcing the early tender results of its and Perrigo Finance Unlimited Company’s, its wholly-owned finance subsidiary (“Perrigo Finance”), cash tender offer (the “Tender Offer”) for up to a combined aggregate principal amount of $1,400,000,000 of Perrigo’s 4.000% Notes due 2023 and 5.300% Notes due 2043 and Perrigo Finance’s 3.500% Notes due March 2021, 3.500% Notes due December 2021, 4.900% Notes due 2044, 4.375% Notes due 2026 and 3.900% Notes due 2024. The press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

Additionally, on June 14, 2017, Perrigo issued a press release announcing the reference yield and total consideration for each series of notes subject to the Tender Offer. The press release is attached as Exhibit 99.2 hereto and incorporated herein by reference.

This Current Report on Form 8-K is neither an offer to purchase nor a solicitation of an acceptance of any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

 

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

 

99.1    Press release issued by Perrigo on June 14, 2017.
99.2    Press release issued by Perrigo on June 14, 2017.

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    (Registrant)
    PERRIGO COMPANY PLC
    By:   /s/ Todd W. Kingma
Dated: June 14, 2017       Todd W. Kingma
     

Executive Vice President,

General Counsel and Secretary

Exhibit Index

 

99.1    Press release issued by Perrigo on June 14, 2017.
99.2    Press release issued by Perrigo on June 14, 2017.
 EX-99.1 2 d413961dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Perrigo Company plc Announces Early Tender Results for Cash Tender Offer

DUBLIN, June 14, 2017 /PRNewswire/ — Perrigo Company plc (“Perrigo” or the “Company”) (NYSE; TASE: PRGO) announced today the early tender results as of 5:00 p.m., New York City time, June 13, 2017 (the “Early Tender Deadline”) for the previously announced cash tender offer (the “Tender Offer”) for up to a combined aggregate principal amount of $1,400,000,000 (the “Maximum Amount”) of Perrigo’s 4.000% Notes due 2023 and 5.300% Notes due 2043 and Perrigo Finance Unlimited Company’s, its wholly-owned finance subsidiary (“Perrigo Finance”), 3.500% Notes due March 2021, 3.500% Notes due December 2021, 4.900% Notes due 2044, 4.375% Notes due 2026 and 3.900% Notes due 2024 (collectively, the “Notes”).

The principal amount of each series of Notes that were validly tendered and not validly withdrawn in the Tender Offer as of the Early Tender Deadline for each Acceptance Priority Level being repurchased is set forth in the table below. No Notes associated with Acceptance Priority Levels 5 and 6 are being repurchased. Perrigo and Perrigo Finance have amended the terms of the Tender Offer to increase the series cap for the 3.500% Notes due March 2021 and 3.500% Notes due December 2021 from an aggregate principal amount of $300,000,000 to an aggregate principal amount of $410,000,000.

 

Issuer/Applicable
Offeror

  

Title of Security

   CUSIP Number   Aggregate Principal
Amount
Outstanding		   Acceptance
Priority
Level		   Series Cap   Principal
Amount
Tendered
Perrigo Company plc   4.000% Notes due 2023   714294AD7   $800,000,000   1   N/A   $584,381,000
Perrigo Company plc   5.300% Notes due 2043   714294AH8   $400,000,000   2   N/A   $309,501,000
Perrigo Finance Unlimited Company  

3.500% Notes due March 2021/

3.500% Notes due December 2021

   71429MAA3/

714295AB8

   $500,000,000/

$500,000,000

   3   $410,000,000

(in aggregate
principal
amount)

   $360,707,000

$314,427,000

Perrigo Finance Unlimited Company   4.900% Notes due 2044   714295AA0   $400,000,000   4   $150,000,000

(in aggregate
principal
amount)

   $341,110,000

The settlement for the Notes validly tendered and not withdrawn on or before the Early Tender Deadline and accepted for purchase by Perrigo and Perrigo Finance is expected to take place on June 15, 2017 (the “Initial Settlement Date”). Holders whose Notes are accepted for purchase will receive the consideration to be calculated at 11:00 a.m., New York City time, on June 14, 2017. The principal amount of each series of Notes that is purchased on the Initial Settlement Date will be determined in accordance with the acceptance priority levels, the applicable series caps and the proration procedures described in the Offer to Purchase, dated May 31, 2017 (the “Offer to Purchase”).

The Tender Offer will expire at 11:59 p.m., New York City time, on June 27, 2017, unless extended (such date and time, as the same may be extended, the “Expiration Time”). However, as Perrigo and Perrigo Finance intend, subject to the terms and conditions of the Tender Offer, to accept for purchase the Maximum Amount of Notes on the Initial Settlement Date, further tenders of Notes prior to the Expiration Time will only be accepted for purchase if Perrigo and Perrigo Finance amend the Tender Offer to increase the Maximum Amount above the principal amount of Notes tendered as of the Early Tender Deadline. Subject to applicable law, the Tender Offer may be amended, extended, terminated or withdrawn with respect to one or more series of Notes.

The obligation of Perrigo and Perrigo Finance to accept for purchase, and to pay for, any Notes validly tendered (and not validly withdrawn) and accepted for purchase pursuant to the Tender Offer is conditioned upon the satisfaction or waiver of the conditions described in the Offer to Purchase under the heading “Terms of the Tender Offer—Conditions of the Tender Offer.”

This press release is neither an offer to purchase nor a solicitation of an acceptance of securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The Tender Offer is being made solely pursuant to terms and conditions set forth in the Offer to Purchase.

Barclays Capital Inc., Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC are serving as the Lead Dealer Managers in connection with the Tender Offer. Wells Fargo Securities, LLC is serving as the Co-Dealer Manager in connection with the Tender Offer. Questions regarding the Tender Offer may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect), Citigroup Global Markets Inc. at (800) 558-3745 (toll free) or (212) 723-6106 (collect) or to Morgan Stanley & Co. LLC at (800) 624-1808 (toll free) or (212) 761-1057 (collect). Requests for the Offer to Purchase or the documents incorporated by reference therein may be directed to D.F. King & Co., Inc., which is acting as Tender Agent and Information Agent for the Tender Offer, at the following telephone numbers: banks and brokers, (212) 269-5550; all others toll free at (800) 967-5071 or at the following email: prgo@dfking.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release are “forward-looking statements.” These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including the timing and expense to complete the Tender Offer. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2016, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Perrigo

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world’s largest manufacturer of over-the-counter (“OTC”) healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of “extended topical” prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America, Europe and Australia, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

For further information: Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, (269) 686-3373, E-mail: bradley.joseph@perrigo.com

EX-99.2 3 d413961dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

Perrigo Company plc Announces Pricing for its Cash Tender Offer

DUBLIN, June 14, 2017 /PRNewswire/ — Perrigo Company plc (“Perrigo” or the “Company”) (NYSE; TASE: PRGO) announced today the reference yield and total consideration for each series of notes subject to the previously announced cash tender offer (the “Tender Offer”) for up to a combined aggregate principal amount of $1,400,000,000 (the “Maximum Amount”) of Perrigo’s 4.000% Notes due 2023 and 5.300% Notes due 2043 and Perrigo Finance Unlimited Company’s, its wholly-owned finance subsidiary (“Perrigo Finance”), 3.500% Notes due March 2021, 3.500% Notes due December 2021, 4.900% Notes due 2044, 4.375% Notes due 2026 and 3.900% Notes due 2024 (collectively, the “Notes”).

The Tender Offer is being made pursuant to, and subject to the terms and conditions in, an Offer to Purchase, dated May 31, 2017, which sets forth a description of the terms of the Tender Offer.

The reference yields for the Tender Offer were determined at 11:00 a.m., New York City time, today. The consideration to be paid in the Tender Offer for each series of Notes being purchased is based on the applicable reference yield plus a fixed spread, as set forth in the table below. Holders who validly tendered and did not validly withdraw Notes at or prior to the Early Tender Deadline (as defined below) that are accepted for purchase will receive the total consideration, which includes an early tender premium of $30 per $1,000 principal amount of Notes accepted for purchase (the “Early Tender Premium”). Holders whose Notes are accepted for purchase pursuant to the Tender Offer will also receive accrued and unpaid interest on their purchased Notes from, and including, the last interest payment date for such Notes to, but excluding, the applicable settlement date. Perrigo and Perrigo Finance expect to accept for purchase a combined aggregate principal amount of $1,400,000,000 of Notes. All of the Notes in Acceptance Priority Levels 1 and 2 that were validly tendered prior to the Early Tender Deadline are expected to be accepted for purchase. The proration factor for the Notes in Acceptance Priority Level 3 will be approximately 57.9% and the proration factor for the Notes in Acceptance Priority Level 4 will be approximately 26.6%. No Notes in Acceptance Priority Levels 5 and 6 are being purchased.

 

Issuer/Applicable
Offeror		   Title of Security   CUSIP
Number		   Aggregate
Principal
Amount
Outstanding		   Acceptance
Priority
Level		   Series Cap   Aggregate
Principal
Amount
Expected to be
Accepted for
Purchase		   Reference
U.S.
Treasury
Security		   Bloomberg
Reference
Page(1)		   Fixed
Spread
(basis
points)		   Reference
Yield		   Total
Consideration(1)(2)
Perrigo Company plc   4.000% Notes

due 2023

   714294AD7   $800,000,000   1   N/A   $584,381,000   1.75% due

5/31/2022

   PX1   100   2.676%   $1,074.82
Perrigo Company plc   5.300% Notes
due 2043		   714294AH8   $400,000,000   2   N/A   $309,501,000   3.00% due
2/15/2047		   PX1   170   4.476%   $1,125.60
Perrigo Finance
Unlimited Company		   3.500% Notes
due March 2021/

3.500% Notes
due December 2021

   71429MAA3/

714295AB8

   $500,000,000/

$500,000,000

   3   $410,000,000

(in aggregate

principal

amount)

   $219,637,000

$190,354,000

   1.75% due
5/31/2022		   PX1

PX1

   50

60

   2.176%

2.276%

   $1,046.41

$1,050.26

Perrigo Finance
Unlimited Company		   4.900% Notes
due 2044		   714295AA0   $400,000,000   4   $150,000,000

(in aggregate
principal
amount)

   $96,127,000   3.00% due
2/15/2047		   PX1   175   4.526%   $1,057.95

 

  (1) Per $1,000 principal amount of Notes. Includes the Early Tender Premium.
  (2) In addition, holders will receive accrued and unpaid interest to the settlement date.

The Tender Offer will expire at 11:59 p.m., New York City time, on June 27, 2017, unless extended (such date and time, as the same may be extended, the “Expiration Time”). Holders of Notes must have validly tendered and not validly withdrawn their Notes at or before 5:00 p.m., New York City time, on June 13, 2017 (the “Early Tender Deadline”) to be eligible to receive the Early Tender Premium for their tendered Notes. After such time, the Notes may not be withdrawn except in certain limited circumstances where additional withdrawal rights are required by law. Assuming the Tender Offer is not extended and the conditions to the Tender Offer are satisfied or waived, Perrigo and Perrigo Finance expect that settlement for Notes validly tendered and not validly withdrawn on or before the Early Tender Deadline and accepted for purchase will be on June 15, 2017.

As Perrigo and Perrigo Finance intend, subject to the terms and conditions of the Tender Offer, to accept for purchase the Maximum Amount of Notes tendered at or prior to the Early Tender Deadline, further tenders of Notes prior to the Expiration Time will not be accepted for purchase.

The obligation of Perrigo and Perrigo Finance to accept for purchase, and to pay for, any Notes validly tendered (and not validly withdrawn) and accepted for purchase pursuant to the Tender Offer is conditioned upon the satisfaction or waiver of the conditions described in the Offer to Purchase under the heading “Terms of the Tender Offer—Conditions of the Tender Offer.”

This press release is neither an offer to purchase nor a solicitation of an acceptance of securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The Tender Offer is being made solely pursuant to terms and conditions set forth in the Offer to Purchase.

Barclays Capital Inc., Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC are serving as the Lead Dealer Managers in connection with the Tender Offer. Wells Fargo Securities, LLC is serving as the Co-Dealer Manager in connection with the Tender Offer. Questions regarding the Tender Offer may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect), Citigroup Global Markets Inc. at (800) 558-3745 (toll free) or (212) 723-6106 (collect) or to Morgan Stanley & Co. LLC at (800) 624-1808 (toll free) or (212) 761-1057 (collect). Requests for the Offer to Purchase or the documents incorporated by reference therein may be directed to D.F. King & Co., Inc., which is acting as Tender Agent and Information Agent for the Tender Offer, at the following telephone numbers: banks and brokers, (212) 269-5550; all others toll free at (800) 967-5071 or at the following email: prgo@dfking.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release are “forward-looking statements.” These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including the timing and expense to complete the Tender Offer. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2016, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Perrigo

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world’s largest manufacturer of over-the-counter (“OTC”) healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of “extended topical” prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America, Europe and Australia, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

For further information: Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, (269) 686-3373, E-mail: bradley.joseph@perrigo.com

GRAPHIC 4 g413961g39z49.jpg GRAPHIC begin 644 g413961g39z49.jpg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end